Effect of Aronia Berry Consumption on Inflammatory Parameters
NCT06702696
Summary
The study will aim to evaluate the effects of consuming freeze-dried aronia berries as an adjunct to medical treatment in patients with chronic obstructive pulmonary disease (COPD), focusing on anti-inflammatory, respiratory, and biochemical parameters. It will be conducted at a research hospital in Istanbul, involving 50 participants aged 50-80 diagnosed with COPD. Participants will be randomly assigned to two groups: the aronia group (AG, n=25) and the placebo group (PG, n=25). The AG will receive 30 g of freeze-dried aronia powder daily, while the PG will receive 30 g of placebo powder, both for a duration of 8 weeks. Baseline demographic data will be collected through face-to-face interviews, while biochemical, respiratory, anthropometric, and body composition parameters will be assessed both before and after the intervention. Dietary intake records will also be collected and analyzed.
Eligibility
Inclusion Criteria: * Aged 50-80 years * Diagnosed with COPD * Not following a vegetarian or vegan diet * Willing to consume the provided aronia berry (black chokeberry) * Non-smokers * Have signed the informed consent form * Has not undergone endobronchial tube or valve surgery in the last two years. Exclusion Criteria: * Presence of associated chronic inflammatory/rheumatic diseases * Chronic infections that may create a prothrombotic state * Chronic kidney disease (CKD) * Malignancy * Hereditary thrombophilia * Essential thrombocythemia * Diagnosed endocrine disorders * Malabsorption disorders * Allergy to any food or berry fruits * Smoking * Participants who did not sign the informed consent form
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06702696